A. G. Goncharova - Dr. Sc. (Med.), Institute of Niomedical Problems, the State Scientific Center of the Russian Federation and Federal State Budgetary Institution of Science, Moscow. E-mail: anig@front.ru Yu. I. Voronkov - Dr. Sc. (Med.), Professor, Institute of Niomedical Problems, the State Scientific Center of the Russian Federation and Federal State Budgetary Institution of Science I. E. Zykova - Dr. Sc. (Med.), Director, Autonomous Nonprofit Organization Center Medicoecology Problem Russian Academy of Natural Sciences, Moscow. E-mail: zmep@list.ru L. Kh. Bragin - Dr. Sc. (Med.), Institute of Niomedical Problems, the State Scientific Center of the Russian Federation and Federal State Budgetary Institution of Science. E-mail: bragin_leonid@mail.ru G. A. Tikhonova - Ph.D. (Med.), Institute of Niomedical Problems, the State Scientific Center of the Russian Federation and Federal State Budgetary Institution of Science D. L. Bragin - Research Scientist, Institute of Niomedical Problems, the State Scientific Center of the Russian Federation and Federal State Budgetary Institution of Science. E-mail: dmitry.bragin@gmail.com

Simulation of the main risk factors in IBMP experiments as well as the real manned space flight results indicate the possibility of development of insulin resistance and associated conditions classified as metabolic syndrome. A total of 58 men aged 35 - 5 with metabolic syndrome and with 10 to 20 years work experience in \"extreme conditions\" were studied. Treatment with telmisartan, losartan and enalapril in combination with bisoprolol, small doses of spironolactone and diuretics allowed to achieve full control of BP and HR without changing conditions. Cardioprotective, angioprotective and renoprotective effects of such combined treatment were marked. This allowed us to consider the remodeling processes of the cardiovascular and endocrine systems as adaptation to changed life conditions as well as to combined treatment during continuing high-intensity work and emotional stress.

 

1. Algoritmy specializirovannojj medicinskojj pomoshhi bolnym sakharnym diabetom / pod red. I.I. Dedova, M.V. SHestakovojj. Izd. 6-e. M., 2013.
2. Volkova A.E., Malygina O.F. Nekotorye problemy profilaktiki i lechenija sakharnogo diabeta tipa 2 // Cons.Med. 2014. V. 5 (16). P. 105-112.
3. Drapkina O.M., Popova I.R. Rol ozhirenija v razvitii arterialnojj gipertenzii i nealkogolnojj zhirovojj bolezni pecheni // Consilium medicum 2012. T.12. № 14. S.72-75.
4. Korneeva O.N., Drapkina O.M. Nealkogolnaja zhirovaja bolezn pecheni u pacientov s metabolicheskim sindromom // Rossijjskijj ZHurnal gastroehnterologii, gepatologii, koloproktologii. (Pril. 29). 2007. T17 (1). S. 65.
5. Oganov R.G., Aleksandrov A.A. Giperinsulinemija i arterialnaja gipertenzija: vozvrashhajas k vyvodam // Russkijj medicinskijj zhurnal. 2001. T. 7 (30). S. 6-10.
6. Podachnina S.V. Samokontrol kak metod lechenija sakharnogo diabeta: Spravochnik poliklinicheskogo vracha. M. 2014.6. S.21-23.
7. Titov V.N.Filogeneticheskaja teorija patologii. Obshhnost stanovlenija v filogeneze patogeneza ehssencialnojj arterialnojj gipertonii i sindroma rezistentnosti k insulinu // Sistemnye gipertenzii. 2014. T. 11. № 3. S. 53-60.
8. SHestakova M.V., Zilov A.V. Vybor optimalnojj sakharosnizhajushhejj terapii u pacientov s sakharnym diabetom tipa 2 v debjute zabolevanija // Consilium medicum 2010. T. 12.  № 12. S. 5-10.
9. Li GW, Hu ZX et al.Effect of diet and exercise in prevention NIDDM in people with impaired glucose tolerance: the DaQing IGT and diabetes study // Diabetes Care 2007. V. 30. R. 744-54.